华兰疫苗：拟使用不超10.00亿元部分闲置募集资金进行现金管理

Core Viewpoint - The company has approved the use of idle raised funds for cash management, ensuring it does not affect the progress of investment projects or normal operations [1] Group 1: Cash Management Approval - The company will continue to use up to RMB 1 billion of idle raised funds for cash management [1] - The investment products will include high safety, good liquidity, and principal-protected options such as structured deposits and large certificates of deposit, with a maturity not exceeding 12 months [1] - The cash management will be effective for 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1]